IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients
This study has been terminated.
Sponsor:
University Hospital, Angers
Information provided by:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT00188045
First received: September 12, 2005
Last updated: December 28, 2005
Last verified: December 2001
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study was assesment of splanchnic and systemic hemodynamic effects of chronic administration (2 month) of spironolactone or propranolol, alone or in association in alcoholic cirrhotic patients. The patients were randomized in 4 groups (aldactone 150 mg/day, propranolol 160 mg/day, aldactone 150 mg/day + propranolol 160 mg/day, placebo). Systemic and splanchnic hemodynamic effect were evaluated by hepatic venous pressure gradient measurements before and after 2 month of treatment.
| Condition | Intervention | Phase |
|---|---|---|
| Alcoholic Cirrhosis | Drug: Propranolol - Spironolactone | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention |
| Official Title: | Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients |
Resource links provided by NLM:
Genetics Home Reference related topics:
North American Indian childhood cirrhosis
U.S. FDA Resources
Further study details as provided by University Hospital, Angers:
Primary Outcome Measures:
- assessment of hepatic veinous pressure gradient changes after chronic treatment by spironolactone or propranolol alone or in association.
Secondary Outcome Measures:
- Efficacy of spironolactone/propranolol association
| Estimated Enrollment: | 54 |
| Study Start Date: | April 1995 |
| Estimated Study Completion Date: | December 2003 |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Indication of transjugular hepatic biopsy
- alcoholic cirrhosis
- presence of oesophageal varices ≤ stade 2
Exclusion Criteria:
- renal insufficiency
- natremia ≤ 135 mmol/l
- vasoactive treatment in the last month before inclusion
- hepatocellular carcinoma
- positive HIV and HCV patients
- paracentesis in the last week before inclusion
- digestive bleeding in one last week
- oesophageal varices stade 3 or 2 with red signs
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188045
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188045
Sponsors and Collaborators
University Hospital, Angers
Investigators
| Principal Investigator: | Paul Cales, PHD | UH Angers |
More Information
| ClinicalTrials.gov Identifier: | NCT00188045 History of Changes |
| Other Study ID Numbers: |
PHRC 01-13 |
| Study First Received: | September 12, 2005 |
| Last Updated: | December 28, 2005 |
Keywords provided by University Hospital, Angers:
|
Portal hypertension, alcoholic cirrhosis, Hepatic venous pressure gradient, hemodynamic, spironolactone, propranolol |
Additional relevant MeSH terms:
|
Fibrosis Liver Cirrhosis, Alcoholic Pathologic Processes Liver Cirrhosis Liver Diseases Digestive System Diseases Liver Diseases, Alcoholic Alcohol-Induced Disorders Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Propranolol Spironolactone Adrenergic beta-Antagonists |
Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Mineralocorticoid Receptor Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Diuretics, Potassium Sparing Diuretics Natriuretic Agents |
ClinicalTrials.gov processed this record on September 18, 2017